N-(biphenyl-4-yl)-N-(4′-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine

We are N-(biphenyl-4-yl)-N-(4′-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine CAS:1268621-99-3 manufacturer and supplier in China, Pls send inquiry of to info@nbinno.com of visit www.nbinno.com our official website should you have any interests

Chemical Name:N-(biphenyl-4-yl)-N-(4'-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine
CAS.NO:1268621-99-3
Synonyms:FBBPA
N-(biphenyl-4-yl)-N-(4'-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine
9H-Fluoren-2-amine, N-[1,1'-biphenyl]-4-yl-N-(4'-bromo[1,1'-biphenyl]-4-yl)-9,9-dimethyl-
Molecular Formula:C39H30BrN
Molecular Weight:592.5662
 
Specification:
Appearance:White powder
Assay:≥98.0%
 
Packing:25 kg/drum, can also be packaged according to customer requirements
Storage:Store in a cool, ventilated place
Application:OLED intermediates

N-(biphenyl-4-yl)-N-(4'-broMobiphenyl-4-yl)-9,9-diMethyl-9H-fluoren-2-amine


Related News: In April 2019, Glenmark had received approval from the Drugs Controller General of India (DCGI) for Remogliflozin Etabonate after successfully completing Phase-3 clinical trials.3-Bromo-5-methylpicolinic acid CAS:1211515-68-2 The slowdown of pesticide intermediates has dragged down the growth of industrial business. In the future, the pharmaceutical intermediate business will be the focus of the company’s development.2-Bromo-1-(4-methylsulfanylphenyl)ethanone Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.3-Glycidoxypropyltrimethoxysilane Onconova Therapeutics, Inc. and Inceptua Medicines Access (a business unit of the Inceptua Group) recently announced they have entered into a collaboration to make available intravenous rigosertib via a Pre-approval Access Program in selected countries around the world.In the early stage of market development, API companies usually need to strive to become a supply company for pharmaceutical companies after quickly completing product preparations. In the subsequent scale-up of production and market application, the relationship between pharmaceutical companies and API companies will become closer. The choice of R & D products of pharmaceutical companies will also be affected by pharmaceutical companies in turn.

Related Products
Product Name
Methyl L-threoninate hydrochloride View Details
chloromethyl(trimethyl)silane View Details
(4S,5R)-2-(4-methoxyphenyl)-3-[(2-methylpropan-2-yl)oxycarbonyl]-4-phenyl-1,3-oxazolidine-5-carboxylic acid View Details
(4S)-4-propan-2-yl-1,3-oxazolidine-2,5-dione manufacturer 1-(2′,5′-DICHLOROPHENYL)-3-METHYL-5-PYRAZOLONE manufacturer 9-Bromo-7,7-dimethyl-7H-benzo[c]fluorene manufacturer (2R)-4-hydroxypentyl-2-ynoic acid benzyl ester manufacturer 4-Chloro-1-methylpiperidine hydrochloride manufacturer